Breaking News, Collaborations & Alliances

Apellis Forms Collaboration with SFJ Pharmaceuticals

For APL-2 in hematologic indications; Apellis to receive up to $120 million in upfront and near-term milestone payments

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Apellis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, has entered a collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals, a global drug development company backed by Blackstone Life Sciences and Abingworth.   This collaboration marks the first time that SFJ Pharmaceuticals has partnered with a pre-revenue biopha...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters